search

Personalis Inc (PSNL)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
PERSONALIS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Personalis, Inc.’s Directors and Officers for Breach of Fiduciary Duties – PSNL
Nov 9, 2026

PERSONALIS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Personalis, Inc.’s Directors and Officers for Breach of Fiduciary Duties – PSNL

Scott+Scott Attorneys at Law LLP has initiated an investigation into Personalis, Inc. (NASDAQ: PSNL) concerning whether its officers and directors breached their fiduciary duties by approving a buyout by Tempus AI, Inc. for inadequate consideration of $16.25 per share. The firm is seeking to represent shareholders who believe they have suffered damages as a result of this proposed acquisition, which was announced on July 20, 2026. Shareholders are encouraged to contact attorney Joseph A. Pettigrew for more information.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Bearish
Personalis: Q3 Earnings Snapshot
Nov 4, 2026

Personalis: Q3 Earnings Snapshot

Personalis Inc. (PSNL) reported a loss of $33.8 million in its third quarter, equating to 32 cents per share. The genomic information provider, based in Fremont, California, also posted revenue of $25.6 million for the period. This financial summary was generated using data from Zacks Investment Research.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Bearish